IL2 and neoplasm: Therefore, the reduction in IL-2 circulating levels observed at M5 in patients under UM, and at M4 and M5 for dogs undergoing UM and OH, can lead to the suppression of cellular immunity, facilitating tumour recurrences and metastases [28].